Thursday, August 2, 2018

Neurocrine Biosciences - 2 Blockbusters Approved, And Likely More To Come

Mid-cap biotech Neurocrine Biosciences (NBIX) continues to rack up the good news, but the market is still reluctant to give full value to the shares. Not only will this company have two presumptive blockbusters-to-be on the market this year, but it will soon be profitable at the operating income line and it has two more potential blockbuster indications lined up relatively soon, as well as longer-dated and more speculative pipeline opportunities. Although the company continues to take what I see as a conservative approach with its pipeline, the switchover to positive free cash flow will create expanded opportunities for capital deployment for management.

Read the full article here:
Neurocrine Biosciences - 2 Blockbusters Approved, And Likely More To Come

No comments: